CVS Health stock: Leerink cuts target for CVS Health stock from USD 119.00 to USD 112.00

Published on 10/19/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health results are due November 4, 2026. CVS Health stock costs EUR 82.50 on October 19, 2026, minus 0.34 percent versus the Xetra close.

Target and reporting date

Leerink Partners lowered its target from USD 119.00 to USD 112.00 on October 12, 2026.
CVS Health will discuss third-quarter 2026 results on November 4, 2026.
CVS Health stock costs EUR 82.50 at Lang & Schwarz on October 19, 2026 at 4:01 p.m. CEST, minus 0.34 percent versus the Xetra close of October 16, 2026.
CVS Health had a market capitalization of USD 118.1 billion and a P/E ratio of 24.51 on October 19, 2026.

Fotorealistisches CGI-Rendering eines modernen Glas-Stahl-Bürogebäudes mit Grünanlage — CVS Health Corp. modernes Unternehmensgebäude als Architektur-Render mit moderner Glas-Stahl-Fassade, ISIN US1266501006, Illustration mit AI erstellt.

Leerink Partners lowered its CVS Health price target from USD 119.00 to USD 112.00 on October 12, 2026, while retaining an outperform rating, according to MarketBeat. At the USD 92.35 NYSE price on October 19, 2026 at 10:04 a.m. EDT, the new target was 21.28 percent above the price. CVS Health stock was trading at EUR 82.50 at Lang & Schwarz on October 19, 2026 at 4:01 p.m. CEST, minus 0.34 percent versus the Xetra close of October 16, 2026 (EUR 82.78).

November 4 sets the next date

CVS Health will discuss its third-quarter 2026 financial results on November 4, 2026, at 8:00 a.m. ET. The company announced the date on October 5, 2026, in a release carried by CVS Health. The appointment gives the next scheduled checkpoint for the health insurer, pharmacy benefit manager and retail pharmacy operator.

For the second quarter of 2026, revenue reached USD 106.10 billion, up 7.30 percent from the year-earlier quarter, while fiscal 2026 adjusted earnings-per-share guidance stood at USD 7.90 to USD 8.10, according to MarketBeat. Those figures provide the operating backdrop for the November report.

Stock sits below its yearly midpoint

The NYSE quote was USD 92.35 at 10:04 a.m. EDT on October 19, 2026, with a session range of USD 91.08 to USD 92.71. Trading volume was 501,506 shares against an average volume of 8,125,296 shares in the same quote.

The 52-week range was USD 69.51 to USD 110.68 on October 19, 2026. The price stood 16.56 percent below the 52-week high and 32.86 percent above the 52-week low. The euro quote therefore places the German trading view below the latest annual high without changing the underlying NYSE currency comparison.

Valuation and analyst distance

CVS Health had a market capitalization of USD 118.1 billion and a price-to-earnings ratio of 24.51 on October 19, 2026. Its trailing dividend yield was 3.00 percent. Leerink's USD 112.00 target remains the clearest dated analyst reference in the recent coverage, while the October 12 note also retained an outperform rating.

Comparison with peers

CVS Health Corp.: minus 0.34 percent, P/E 24.51, market capitalization USD 118.1 billion

UnitedHealth Group Incorporated (NYSE, USD): plus 1.21 percent, P/E 23.25, market capitalization USD 364.7 billion

Cigna Corporation (NYSE, USD): minus 0.52 percent, P/E 12.49, market capitalization USD 79.5 billion

Price remains the daily frame

The USD 112.00 target is 21.28 percent above the NYSE price, while the euro quote was 0.34 percent below the Xetra close of October 16, 2026. That contrast keeps the analyst target and the November reporting date more relevant than the small intraday euro move.

The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.